详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

The relationship between EGFR mutation status and clinic-pathologic features in pulmonary adenocarcinoma

4| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China [2]Department of Medical Record Management, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China

出处：

DOI：

ISSN：

关键词： Adenocarcinoma Epidermal growth factor receptor Lung cancer Mutation Pathological features Prognosis

摘要：

To detect the relationship of the epidermal growth factor receptor (EGFR) mutation status and the clinicopathologic features. Six hundred thirty-three patients with pathologically confirmed lung adenocarcinoma who underwent lung cancer resection surgery at the Fourth Hospital of Hebei Medical University between April 2012 and April 2015 were selected for the study. The 32 types of mutations in exons 18-21 of the EGFR gene were detected. The total EGFR mutation rate among patients with lung adenocarcinoma was 56.9%. The mutation rates were 71.2% among females and 42.8% among males (P < 0.05). Among patients with TNM stage I, II, III, and IV disease, the EGFR mutation rates were significant differences (P < 0.05). Concerning different subtypes of lung adenocarcinoma, the EGFR mutation rates were differences, and these differences were statistically significant (P < 0.05). Cox multivariate regression model analysis considering EGFR mutation status revealed that differences in TNM stage (P < 0.01), smoker status, and tumor size were statistically significant predictors. Patients with minimally invasive and lepidic adenocarcinomas were categorized as low-risk group with high EGFR mutation rate; Patients with micro-papillary and solid adenocarcinomas were categorized as high-risk with lower EGFR mutation rate, so there are different mechanisms in different types of adenocarcinomas.

语种：

被引次数：

WOS：

PubmedID：

中科院分区：

出版当年[2018]版：

大类 | 4 区医学

小类 | 4 区病理学

最新[2025]版：

大类 | 4 区医学

小类 | 3 区病理学

JCR分区：

出版当年[2018]版：

Q3 PATHOLOGY

最新[2023]版：

Q2 PATHOLOGY

影响因子： 2.9 最新[2023版] 2.6 最新五年平均 1.794 出版当年[2018版] 1.635 出版当年五年平均 1.466 出版前一年[2017版] 2.05 出版后一年[2019版]

第一作者：

第一作者机构： [1]Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China

通讯作者：

通讯机构： [1]Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China [*1]Department of Pathology, The Fourth Hospital of Hebei Medical University, No. 12, Jiankang Road, Shijiazhuang, 050011, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma [2]Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report [3]伴表皮生长因子受体基因突变的肺腺癌转移至口腔两例 [4]EGFR基因突变阳性肺腺癌脑转移患者治疗后颅内失败的临床研究 [5]The Association between Epidermal Growth Factor Receptor Single Nucleotide Polymorphisms and Radiochemotherapy Response in Cervical Cancer [6]Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE) [7]Significance of EGFRGene Mutation in Fresh Cytological Specimens of Lung Adenocarcinoma [8]A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutation [9]Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study [10]Erlotinib vs etoposide/cisplatin with radiotherapy in unresectable stage III epidermal growth factor receptor mutation-positive non-small-cell lung cancer: A multicenter, randomized, open-label, phase 2 trial.